一项研究发现,Celecoxib提高了CtDNA-阳性三级结肠癌患者的存活率。 A study finds celecoxib improves survival rates for ctDNA-positive stage III colon cancer patients.

最近的一项研究表明,对循环肿瘤脱氧核糖核酸(ctDNA)进行血液测试,可以帮助确定第三级结肠癌病人,他们可能从该药物的蛋白质中得益。 A recent study shows that a blood test for circulating tumor DNA (ctDNA) can help identify stage III colon cancer patients who may benefit from the drug celecoxib. 在ctDNA阳性患者中,与安慰剂患者相比,服用西莱科西布并配合标准化疗的患者在无疾病生存率显著提高. Among patients with ctDNA-positive results, those who took celecoxib alongside standard chemotherapy had significantly better disease-free survival rates compared to those who took a placebo. 这表明,切莱科克西布可以作为某些早期结肠癌患者治疗的宝贵补充,提供个性化治疗选择. This suggests that celecoxib could be a valuable addition to treatment for certain early-stage colon cancer patients, offering personalized therapy options.